Search clinical trials for: SPRX002

Total 26 results

Arcellx, Inc.

Recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Parkinson's Disease

United States
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA)

Parkinson's Disease

United States, Spain, France, Germany, Austria
Sophiris Bio Corp

Completed

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Locally Recurrent Prostate Cancer

United States
Sophiris Bio Corp

Completed

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Prostate Cancer

United Kingdom, United States
Prothena Biosciences Limited

Terminated

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Amyloidogenic Transthyretin (ATTR) Amyloidosis

United States, Spain, Sweden, Portugal
Shin Poong Pharmaceutical Co. Ltd.

Active, not recruiting

Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Osteoarthritis

Korea, Republic of
Sophiris Bio Corp

Completed

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Prostate Cancer

United Kingdom
Sophiris Bio Corp

Completed

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

United States
Sophiris Bio Corp

Completed

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia (TRIUMPH-1)

Benign Prostatic Hyperplasia

Canada
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Psoriasis

United States
Sophiris Bio Corp

Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH (PLUS-1)

Benign Prostatic Hyperplasia

United States, Australia, Canada, Russian Federation, Ukraine, New Zealand
Sophiris Bio Corp

Completed

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

Prostate Cancer

United States
Spruce Biosciences

Completed

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Polycystic Ovary Syndrome

United States
Spruce Biosciences

Completed

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia | CAH - Congenital Adrenal Hyperplasia | CAH - 21-Hydroxylase Deficiency

United States
Spruce Biosciences

Completed

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia | CAH - Congenital Adrenal Hyperplasia

United States
Spruce Biosciences

Active, not recruiting

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Congenital Adrenal Hyperplasia

United States, Australia, Brazil, Canada, Denmark, Estonia, Germany, Ireland, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Global Health Drug Discovery Institute
CMAX Clinical Research Pty Limited; Avance Clinical

Completed

SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects

COVID-19

Australia
Spruce Biosciences

Recruiting

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children With CAH

Congenital Adrenal Hyperplasia | 21-OHD

United States
Spruce Biosciences

Active, not recruiting

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Congenital Adrenal Hyperplasia

United States, Australia, Brazil, Estonia, Germany, Korea, Republic of, Latvia, Lithuania, Poland, Romania, Spain, Sweden, Turkey, Canada, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Melanoma

United States
Tong Lee
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

Cocaine Dependence | Methamphetamine Dependence

United States
Futura Medical Developments Ltd.
Parexel

Completed

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model

Pain

United Kingdom
Shin Poong Pharmaceutical Co. Ltd.

Completed

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension (SP-CAP-002)

Hypertension | Essential Hypertension

Korea, Republic of

Search clinical trials for: SPRX002

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations